CN101084003A - 治疗性营养组合物或联合药物及其使用方法 - Google Patents

治疗性营养组合物或联合药物及其使用方法 Download PDF

Info

Publication number
CN101084003A
CN101084003A CNA2005800440212A CN200580044021A CN101084003A CN 101084003 A CN101084003 A CN 101084003A CN A2005800440212 A CNA2005800440212 A CN A2005800440212A CN 200580044021 A CN200580044021 A CN 200580044021A CN 101084003 A CN101084003 A CN 101084003A
Authority
CN
China
Prior art keywords
glutamine
composition
patient
concentration
per liter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800440212A
Other languages
English (en)
Chinese (zh)
Inventor
D·K·海兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRITICAL CARE CONNECTIONS Inc
Original Assignee
CRITICAL CARE CONNECTIONS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRITICAL CARE CONNECTIONS Inc filed Critical CRITICAL CARE CONNECTIONS Inc
Publication of CN101084003A publication Critical patent/CN101084003A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800440212A 2004-12-21 2005-12-21 治疗性营养组合物或联合药物及其使用方法 Pending CN101084003A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63765704P 2004-12-21 2004-12-21
US60/637,657 2004-12-21

Publications (1)

Publication Number Publication Date
CN101084003A true CN101084003A (zh) 2007-12-05

Family

ID=36601322

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800440212A Pending CN101084003A (zh) 2004-12-21 2005-12-21 治疗性营养组合物或联合药物及其使用方法

Country Status (9)

Country Link
US (1) US20080131525A1 (https=)
EP (1) EP1841445A4 (https=)
JP (2) JP2008524123A (https=)
CN (1) CN101084003A (https=)
AU (1) AU2005318832B2 (https=)
BR (1) BRPI0519755A2 (https=)
CA (1) CA2588911C (https=)
WO (1) WO2006066404A1 (https=)
ZA (1) ZA200705824B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120420344A (zh) * 2025-07-08 2025-08-05 中国人民解放军总医院第三医学中心 一种眼用药物组合物及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004762B2 (en) 2013-05-08 2018-06-26 Gambro Lundia Ab Dialysis formulation
EP3490971A4 (en) * 2016-08-01 2020-02-26 Filament Biosolutions Inc. METHODS OF TREATING AND PREVENTING SIDE EFFECTS OF CANCER TREATMENT
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
DE4304172A1 (de) * 1993-02-12 1994-08-25 Bayer Ag Fungizide Wirkstoffkombinationen
US5561111A (en) * 1994-12-23 1996-10-01 The University Of Virginia Patent Foundation Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
DE69739663D1 (de) * 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US5849335A (en) * 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
US6649746B1 (en) * 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU5625001A (en) * 2000-04-18 2001-10-30 Societe Des Produits Nestle S.A. Nutritional modules
US6479068B1 (en) * 2000-06-30 2002-11-12 Baxter International Inc. Therapeutic nutrient regimen for alleviating mucositis, stomatitis and cachexia in oncology patients
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
US6552076B2 (en) * 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6660293B2 (en) * 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
JP2003192586A (ja) * 2001-12-27 2003-07-09 Ss Pharmaceut Co Ltd ＩＬ−１β抑制剤
DE10221403A1 (de) * 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung
US6645514B1 (en) * 2002-12-19 2003-11-11 Access Business Group International, Llc Increasing skin cell renewal with water-soluble Vitamin E

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120420344A (zh) * 2025-07-08 2025-08-05 中国人民解放军总医院第三医学中心 一种眼用药物组合物及其制备方法和应用
CN120420344B (zh) * 2025-07-08 2025-09-05 中国人民解放军总医院第三医学中心 一种眼用药物组合物及其制备方法和应用

Also Published As

Publication number Publication date
EP1841445A1 (en) 2007-10-10
JP2008524123A (ja) 2008-07-10
JP2012107023A (ja) 2012-06-07
AU2005318832B2 (en) 2011-07-07
WO2006066404A1 (en) 2006-06-29
CA2588911A1 (en) 2006-06-29
AU2005318832A1 (en) 2006-06-29
EP1841445A4 (en) 2010-06-02
BRPI0519755A2 (pt) 2009-03-10
CA2588911C (en) 2013-04-23
US20080131525A1 (en) 2008-06-05
ZA200705824B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
Berger et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations
Denno et al. Glutamine-enriched total parenteral nutrition enhances plasma glutathione in the resting state
HK74697A (en) Pharmaceutical therapeutic use of glutathione derivatives
CN101420933A (zh) 用于胃肠外营养的儿科氨基酸溶液
US5248697A (en) Enhancement of glutathione levels with glutamine
EP3294279A1 (en) Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
Jain et al. L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet
CA2060560C (en) Method for insuring adequate intracellular glutathione in tissue
JP2012107023A (ja) 治療用栄養組成物又は組合せ、及びそれらの使用方法
KR20100015922A (ko) 암 환자용 수액 제제
WO2008151520A1 (en) A use of sodium selenosulfate for supplementing selenium and enhancing the cure effectiveness of chemotherapy agents,and the rapidly preparing method thereof
EP1868572A2 (en) Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
HK1111106A (en) Therapeutic nutrient compositions or combinations and methods of their use
ES2651903T3 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento del estado inflamatorio sistémico asociado con el accidente cerebrovascular en pacientes con disfagia
KR20110087614A (ko) 산화적 스트레스의 감소를 위한 정맥주사 수액제
EP2556828B1 (en) Composition for amelioration of hypoalbuminemia
Valencia et al. Practicalities of glutathione supplementation in nutritional support
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
Fuhrman et al. Reactive Oxygen Species and Glutathione: Potential for Parenteral Nutrition Supplementation?
AU2004298299A1 (en) A treatment for necrotizing enterocolitis
Mühling et al. Effects of diazepam on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Metabolical and immunological consequences of L-alanyl-L-glutamine supplementation
EP3797784A1 (en) Anti-coagulant agent, blood coagulation improving device, blood coagulation improving method, vascular endothelial cell function improving method, and metabolism improving method
EP4721735A1 (en) Composition for enteral nutrition of cancer patients
Bode et al. Glutamine and C ancer
Grimble THE IMPACT OF DIETARY SULFUR AMINO ACID INTAKE ON IMMUNE FUNCTION IN HEALTH AND DISEASE3

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111106

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: German Homburg

Applicant after: FRESENIUS KABI DEUTSCHLAND GmbH

Address before: Lethbridge Canada

Applicant before: Critical Care Connections, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CRITICAL CARE CONNECTIONS INC. TO: FREZENEWSKABUE GERMANY CO., LTD.

TA01 Transfer of patent application right

Effective date of registration: 20120704

Address after: Lethbridge Canada

Applicant after: Critical Care Connections, Inc.

Address before: Ontario

Applicant before: Critical Care Connections, Inc.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20071205

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1111106

Country of ref document: HK